# Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

> **NCT03691974** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 180 (actual)

## Conditions studied

- Osteoarthritis, Knee
- Osteoarthritis, Hip

## Interventions

- **DRUG:** Fasinumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03691974
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-15
- **Primary completion:** 2020-01-30
- **Final completion:** 2021-01-07
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2023-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691974, "Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT03691974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*